New route to animal health
Summary
The companys revenue generation will be based on licensing and/or co-development agreements with the veterinary pharmaceutical industry.Lille, Wednesday 27th November 2024 Vetbiolix, a veterinary biotechnology company based in France dedicated to the clinical development of First-in-Class drug candidates for the treatment of periodontitis, osteoarthritis and gastric motility disorders in dogs and cats, announces the final results of the proof of concept study of VBX-2000, the first agonist of the adenosine A3 receptor (A3R) in dogs suffering from osteoarthritis, and announces the launch of a double-blind randomized regulatory pilot study blind vs placebo in this indication. Due to this unique positioning in the veterinary therapeutic arsenal, VBX-2000 could become the first-line treatment, allowing global management of the pathology and ultimately improving the mobility and quality of life of dog patients suffering from osteoarthritis. Matthieu Roquette, founder and President of VETBIOLIX indicates: With the positive results of this Proof of Concept clinical study, we are pleased to have respected our commitments made to our partner Can-Fite Biopharma, our investors and the veterinarian community. Finally, the evolution of the alveolar bone defect after 90 days was documented on 60 teeth affected by periodontal disease using two distinct imaging techniques: X-ray radiography and CBCT (Cone Beam Computed Tomography). *p<0,05 ; ***p<0.001 vs D0 according to \xab Dunns multiple comparisons test \xbb The rapid and continued decrease of CTX1 plasma concentration suggested persistent inhibition of the resorption process that may promotes bone healing around affected teeth.